In Part 1, I examined the investor memorandum behind Direct Peptides and the business infrastructure being marketed for sale. If you missed it you can find it here
So You Want to Buy an RUO Peptide Company?
What emerged was a company that looked less like a traditional peptide vendor and more like a highly optimised e-commerce operation built around fulfilment, retention, automation, advertising infrastructure and customer acquisition.
But one question remained. Who exactly is Horizon Analytical and what is their relationship to Direct Peptides?
The name appears throughout the Direct Peptides ecosystem and it's COAs are used to support the company’s testing claims.
The investor memorandum states that Direct Peptides products are tested through Horizon. It also states that Horizon Analytical is not included in the sale because it exists as a separate company. Elsewhere, the memo discusses continuing to use Horizon after ownership transfer and even refers to providing Direct Peptides COAs “at cost.”
That alone makes Horizon more than just a passing reference. It appears to be an important part of the operational structure surrounding Direct Peptides. So I started looking at what could be independently verified. The first thing that stood out was the timeline.
Public trademark records show that Aspire Labs, the owner of the DIRECT PEPTIDES trademark, filed that trademark application on 20 October 2025.
Public domain records show that HorizonAnalytical.com was registered the following day, on 21 October 2025.
One day apart. On its own, that proves nothing. Businesses launch brands, websites and supporting services all the time. But it was enough to justify looking further. The next discovery was more interesting.
The DIRECT PEPTIDES trademark filing lists Aspire Labs at:
6805 Windhaven Pkwy #308
The Colony, Texas 75056
Google Maps currently lists Horizon Analytical at:
6805 Windhaven Pkwy #308
The Colony, Texas 75056
What this established is that the two entities appear to be operating from the same suite address. When that address overlap is viewed alongside the trademark timeline, the investor memorandum references, the Horizon COAs, and customer reports of being directed toward Horizon testing, the relationship becomes difficult to ignore.
The question is no longer whether Horizon Analytical exists. The question becomes “What exactly is the relationship between Direct Peptides, Aspire Labs and Horizon Analytical?”
And what does “third-party tested” mean when the testing layer appears this closely connected to the business itself?
In addition I’m also unable to identify any other peptide companies publicly displaying Horizon COAs or advertising Horizon as their testing provider.
Customer Experience
One customer I spoke to said Direct Peptides was one of the first peptide companies he purchased from when he entered this space. According to the customer, Direct Peptides was responsive throughout the ordering process. What eventually caught his attention was the company’s advertising. After making a purchase, he said he began seeing a large number of advertisements that appeared connected to Direct Peptides.
At one point he became concerned because an Instagram advertisement appeared to direct him somewhere unexpected. Unsure whether he was dealing with the correct website, he contacted the company directly and explained that the link destination seemed different from what he had seen previously.
The response he received was straightforward, “Yes, it’s the same website. If you’re unsure, please feel free to use this link.” He was then provided with a direct link to the DirectPeptides.com product page.
The customer said he ultimately placed orders and received products, but the experience left him with the impression that there was a much larger advertising operation running behind the scenes than most buyers would ever see.
That observation is particularly interesting when viewed alongside the investor memorandum, which openly discusses multiple advertising accounts, backup advertising infrastructure, customer acquisition systems and cloaking strategies designed to maintain advertising continuity. On its own, the customer’s experience proves very little. But it does provide a real-world example of the type of marketing infrastructure described throughout the memo.
Since publishing part 1, the corresponding WebsiteClosers listing has been marked as SOLD. While the identity of the buyer is unknown, the listing that advertised the business for $14.5 million is no longer being marketed as available.
I’ve reposted this with the customer experience removed. While those conversations added context, the core findings don’t depend on them.
The article is based on publicly available information data, business addresses, company websites, investor materials and other independently verifiable sources.
Taken together, those records directly connect Aspire Labs, Direct Peptides and Horizon Analytical in ways that readers can verify for themselves.
The purpose of the article is not to tell people what conclusion to reach. It is simply to present the publicly available evidence, show where the links exist, and allow readers to decide for themselves what those links mean.
Comments